bioXcelerate launches breakthrough AI tool for faster drug discovery

bioXcelerate, a new and innovative health data science division of Optima Partners Limited, has revealed a new groundbreaking AI tool, which is set to accelerate the process for identifying and developing new drugs.

RAPT terminates Phase II trials for lead candidate following clinical hold

RAPT Therapeutics’ zelnecirnon is a C-C motif chemokine receptor 4 (CCR4) agonist. Image Credit: Jennie Book / Shutterstock. RAPT Therapeutics has announced plans to terminate

May 10, 2024

Patients fear judgment for sharing health misconceptions, study finds

When an individual visits their doctor, they aren’t supposed to keep secrets. Unless patients are forthcoming about their symptoms, behaviors, and health-related beliefs, it’s hard

August 4, 2024

Retinal Tumor Risk Incidentally Detected at 29 Weeks’ Gestation

Incidental detection of a genetic abnormality in a fetus at 29 weeks’ gestation was the conundrum facing Ido Didi Fabian, MD, of The Goldschleger Eye

January 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.